C
7.25
-0.06 (-0.82%)
| Previous Close | 7.31 |
| Open | 7.36 |
| Volume | 456,567 |
| Avg. Volume (3M) | 2,969,106 |
| Market Cap | 571,220,608 |
| Price / Earnings (TTM) | 3.28 |
| Price / Earnings (Forward) | 4.68 |
| Price / Sales | 5.94 |
| Price / Book | 3.91 |
| 52 Weeks Range | |
| Earnings Date | 12 Mar 2026 |
| Profit Margin | 20.81% |
| Operating Margin (TTM) | 51.49% |
| Diluted EPS (TTM) | 0.250 |
| Total Debt/Equity (MRQ) | 0.41% |
| Current Ratio (MRQ) | 4.21 |
| Operating Cash Flow (TTM) | -13.57 M |
| Levered Free Cash Flow (TTM) | -21.07 M |
| Return on Assets (TTM) | 8.31% |
| Return on Equity (TTM) | 19.87% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | CorMedix Inc. | Bearish | Mixed |
AIStockmoo Score
1.5
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 3.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company’s focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 1.08% |
| % Held by Institutions | 34.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Oberweis Asset Management Inc/ | 31 Dec 2025 | 805,115 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 15.00 (Needham, 106.90%) | Buy |
| Median | 13.50 (86.21%) | |
| Low | 13.00 (RBC Capital, 79.31%) | Buy |
| 13.00 (HC Wainwright & Co., 79.31%) | Buy | |
| Average | 13.75 (89.66%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 7.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 11 Feb 2026 | 14.00 (93.10%) | Buy | 7.43 |
| 08 Jan 2026 | 14.00 (93.10%) | Buy | 7.51 | |
| HC Wainwright & Co. | 23 Jan 2026 | 13.00 (79.31%) | Buy | 7.27 |
| RBC Capital | 21 Jan 2026 | 13.00 (79.31%) | Buy | 7.33 |
| Needham | 08 Jan 2026 | 15.00 (106.90%) | Buy | 7.51 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | CorMedix Therapeutics Announces Share Repurchase Program |
| 29 Jan 2026 | Announcement | CorMedix Therapeutics to Host In-Person and Virtual Analyst Day in New York on February 10, 2026 |
| 09 Jan 2026 | Announcement | CorMedix Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 08 Jan 2026 | Announcement | CorMedix Therapeutics Announces Leadership and Board Updates |
| 08 Jan 2026 | Announcement | CorMedix Therapeutics Announces Preliminary Fourth Quarter and Full Year 2025 Results and Provides Business Updates |
| 18 Dec 2025 | Announcement | CorMedix Therapeutics Announces Positive Data From Ongoing Real World Evidence Study of DefenCath |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |